Search results
Showing 556 to 570 of 679 results for end of life care
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .
The social care guidance manual
Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease
Find out more about NICE technology appraisals advisory committee D members
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)
Guide to the technology appraisal and highly specialised technologies appeal process
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
mesh complications, it is important to think about your whole quality of life now and what you hope to gain from treatment. Treatment...
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
How we collect and use your personal information, and your rights under data protection legislation.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making